Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angeles Alvarez Secord

Showing results (181-190 of 239) with videos related to

Pageof 24
Sort By:
Gynecologic Oncology|January 31, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tubeThomas J Herzog, Bradley J Monk, Peter G Rose, et al.
Frontiers in Oncology|July 8, 2014
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell LinesBrittany Anne Davidson, Jennifer M Rubatt, David L Corcoran, et al.
Gynecologic Oncology|May 5, 2012
Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centersAmanda Nickles Fader, Leigh G Seamon, Pedro F Escobar, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2026
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancerRobert M Wenham, Andrea L Buras, Sarah W Gordon, et al.
Gynecologic Oncology|February 23, 2025
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progressionAmma Asare, Rebecca Ann Previs, Daniel Spinosa, et al.
Gynecologic Oncology Reports|June 16, 2025
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancersStéphanie L Gaillard, Gloria Broadwater, Andrew Berchuck, et al.
Gynecologic Oncology Reports|August 9, 2021
Placental uterine artery embolization followed by delayed hysterectomy for placenta percreta: A case seriesLuke A Gatta, Paula S Lee, Jennifer B Gilner, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2012
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumorsGordana Vlahovic, Kellen L Meadows, Hope E Uronis, et al.
American Journal of Perinatology|August 16, 2022
Transfusion Requirements with Hybrid Management of Placenta Accreta Spectrum Incorporating Targeted Embolization and a Selective Use of Delayed HysterectomyLuke A Gatta, Jeremy M Weber, Jennifer B Gilner, et al.
Gynecologic Oncology|August 29, 2009
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)Amanda Nickles Fader, David Starks, Paola A Gehrig, et al.
Pageof 24

Showing results (181-190 of 239) with videos related to

Sort By:
Pageof 24
Gynecologic Oncology|January 31, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tubeThomas J Herzog, Bradley J Monk, Peter G Rose, et al.
Frontiers in Oncology|July 8, 2014
Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell LinesBrittany Anne Davidson, Jennifer M Rubatt, David L Corcoran, et al.
Gynecologic Oncology|May 5, 2012
Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centersAmanda Nickles Fader, Leigh G Seamon, Pedro F Escobar, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 20, 2026
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancerRobert M Wenham, Andrea L Buras, Sarah W Gordon, et al.
Gynecologic Oncology|February 23, 2025
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progressionAmma Asare, Rebecca Ann Previs, Daniel Spinosa, et al.
Gynecologic Oncology Reports|June 16, 2025
A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancersStéphanie L Gaillard, Gloria Broadwater, Andrew Berchuck, et al.
Gynecologic Oncology Reports|August 9, 2021
Placental uterine artery embolization followed by delayed hysterectomy for placenta percreta: A case seriesLuke A Gatta, Paula S Lee, Jennifer B Gilner, et al.
Cancer Chemotherapy and Pharmacology|May 29, 2012
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumorsGordana Vlahovic, Kellen L Meadows, Hope E Uronis, et al.
American Journal of Perinatology|August 16, 2022
Transfusion Requirements with Hybrid Management of Placenta Accreta Spectrum Incorporating Targeted Embolization and a Selective Use of Delayed HysterectomyLuke A Gatta, Jeremy M Weber, Jennifer B Gilner, et al.
Gynecologic Oncology|August 29, 2009
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)Amanda Nickles Fader, David Starks, Paola A Gehrig, et al.
Pageof 24